Tresiba FlexTouch 100 E/ml
Tresiba FlexTouch 100 E/ml is a medicine authorised by Swissmedic under authorisation number 62563. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 12 March 2013 and the authorisation is valid without a time limit. ATC code A10AE06 places the medicine in the group Drugs used in diabetes.
| Authorisation number | 62563 |
|---|---|
| Name | Tresiba FlexTouch 100 E/ml |
| Full name | Tresiba FlexTouch 100 E/ml, Injektionslösung |
| Authorisation holder | Novo Nordisk Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | A10AE06 |
| First authorisation | 12 March 2013 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Tresiba FlexTouch 100 E/ml, Injektionslösung | B | 12 March 2013 |
| 2 | Tresiba FlexTouch 200 E/ml, Injektionslösung | B | 12 March 2013 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 5 x 3 | ml | A10AE06 | 07.06.1. | B |
| 2 | 3 x 3 | ml | A10AE06 | 07.06.1. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Tresiba FlexTouch 100 E/ml authorised in Switzerland?
Yes. Tresiba FlexTouch 100 E/ml is authorised by Swissmedic under authorisation number 62563, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Tresiba FlexTouch 100 E/ml have?
Tresiba FlexTouch 100 E/ml is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Tresiba FlexTouch 100 E/ml?
The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.